Squarepoint’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Squarepoint’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-154,976	Closed	-$1.1M	–	2678
2020 Q1	$1.1M	Buy	154,976 +104,321	+206%	+$1.3M	0.03%	682
2019 Q4	$1.21M	Buy	+50,655	New	+$1.4M	0.01%	1223
2019 Q1	–	Sell	-10,501	Closed	-$205K	–	2557
2018 Q4	$205K	Buy	+10,501	New	+$216K	﹤0.01%	1674
2017 Q4	–	Sell	-8,978	Closed	-$485K	–	2442
2017 Q3	$485K	Buy	+8,978	New	+$527K	0.01%	995
2016 Q1	–	Sell	-12,400	Closed	-$638K	–	1559
2015 Q4	$638K	Buy	+12,400	New	+$601K	0.07%	423

Other funds holding PTLA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Squarepoint's PTLA Position: Q2 2020 in Review

Squarepoint sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 154,976 shares — an estimated $1.1M sold.

Squarepoint first reported a position in PTLA in Q4 2015 and held it in 5 quarters. The position peaked at $1.21M in Q4 2019. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

Squarepoint reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Squarepoint sold 154,976 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $1.1M.
Squarepoint first reported a position in Portola Pharmaceuticals, Inc. in Q4 2015 and held it in 5 quarters.
Squarepoint's Portola Pharmaceuticals, Inc. position peaked at $1.21M in Q4 2019.
162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on Squarepoint's 13F filing for Q2 2020, filed 14 Aug 2020.